Cytoo – next generation HCS with physiologically relevant cellular models

Cytoo - next generation HCS with physiologically relevant cellular models

Cytoo –  next generation HCS with physiologically relevant cellular models

In general, complex tissue models reflect the in vivo situation more reliably than simpler 2D or 3D systems. But the higher the complexity, the lower the throughput. Complex models also raise other problems such as validation, reproducibility, image analysis, maintenance, as well as costs. CYTOO has pioneered the ability to control the cellular microenvironment through the use of micropattern technologies. Micropatterning controls cell microenvironment: it enables to choose from several adhesion molecules and attachment areas and geometries, cell densities, and promotes cell-cell junctions. In turn, the physical and biochemical cues received by cells change their genomic transcription and thus their phenotype. Thus, the CYTOO culture platform significantly enhances the physiological relevance of cellular models in comparison to standard techniques used by most labs and CRO’s.

CYTOO’s solutions can transform conventional cellular models grown as heterogeneous monolayers into a more in-vivo like phenotype and morphology through cell micropatterning. This unique approach can then enable simple conversion of poorly predictable and robust, and low throughput assays, into highly reliable and data rich high content screening efforts.

High Content Screening (HCS) is a priority at CYTOO. Its cell-based assays combine robustness, multiplexed visual read-outs and throughput. All the assays developed by this company are 96-well compatible, while the 384 format is coming out soon. This biotech company proposes several kinds of Cell-based assays. Its human myotube cellular model displays a so far unreached level of maturation and standardization which enables robust High Content Screening of atrophy and hypertrophy read outs. Furthermore, its OncoSpheres 3D spheroid models are best-in-class tools for cancer drug profiling as they enable fully automated production and robust High Content Analysis through a one step process.

More about this biotech company : https://cytoo.com/

 

Cytoo – High Content Screening – HCS – physiologically relevant cellular models – Micropatterning – micropattern technology – human myotube cellular model – OncoSpheres 3D spheroid models

Cytoo – High Content Screening – HCS – physiologically relevant cellular models – Micropatterning – micropattern technology – human myotube cellular model – OncoSpheres 3D spheroid models

Cytoo – High Content Screening – HCS – physiologically relevant cellular models – Micropatterning – micropattern technology – human myotube cellular model – OncoSpheres 3D spheroid models